首页>
外国专利>
Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors to reduce harmful effects of perfusion deficiency of organs
Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors to reduce harmful effects of perfusion deficiency of organs
展开▼
机译:中性内肽酶(nep)和人可溶性内肽酶(hsep)抑制剂可减少器官灌注不足的有害影响
展开▼
页面导航
摘要
著录项
相似文献
摘要
The invention relates to a novel use of benzazepine, benzoxazepine, benzothiazepine-N-acetic acid and phosphono-substituted benzazepinone derivatives having both neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP), and endothelin convertase (ECE), inhibitory activity. The compounds of this invention are useful for the preparation of pharmaceutical compositions to reduce harmful effects of symptomless progressive disseminated perfusion deficiency of organs, or parts thereof, that may be suggestive of systemic diseases.
展开▼